(December 14, 2017) For over two decades, you have made it possible for OCRFA to fund the most innovative and promising science, resulting in research breakthroughs that have advanced our understanding of ovarian cancer, how it starts and new treatment options, and you have enabled OCRFA to successfully advocate for federal research dollars and provide … Continued
(December 11, 2017) A study by the Ovarian Tumor Tissue Analysis Consortium, published in JAMA Oncology, looked at the association between cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) and overall survival with certain types of ovarian cancer. After an immunohistochemical analysis of 5,577 patients, researchers saw a strong correlation between high levels of CD8+ TILs and longer … Continued
(December 8, 2017) The results of the CONCORD-2 study, recently published in Cancer, show a large difference in ovarian cancer survival between black women and white women, and also between stages at diagnosis. The data collected from the study, the largest of its kind, looked at 172,849 cases of ovarian cancer, over the course of … Continued
(December 4, 2017) The results of a phase II trial, which focused on stages IIB to IVA epithelial ovarian cancer, were recently published in the Annals of Oncology. The primary purpose of the six year, two stage, multicenter trial was to look at the nine month progressive disease rate when using intraperitoneal (IP) chemotherapy after … Continued
(November 22, 2017) A recent paper published in the Journal of Clinical Investigation reports that a subset of ovarian cancers reduce the expression of a critical gene involved in recycling the cells’ proteins, known as ubiquitin B (UBB). Silencing the expression of a closely related gene, also in the ubiquitin family, that performs an identical … Continued
(October 30, 2017) Until recently, it was thought that high-grade serous ovarian carcinomas (HGSOCs) arose from the ovarian surface epithelium, but recent data from two studies published in Nature Communications suggest that all high grade serous ovarian cancers do in fact originate in the fallopian tube. These findings have implications for ovarian cancer detection and … Continued
(October 20, 2017) An international, large scale study may have found a link between high-grade ovarian cancer and a type of white blood cell known as a tumor-infiltrating lymphocyte. Recently published in JAMA Oncology, the article from the Ovarian Tumor Tissue Analysis Consortium discussed the study, which involved about 5,500 patients, 3,196 of whom had … Continued
(October 19, 2017) BRCA1 and BRCA2 are among the most frequently mutated genes in ovarian cancer. Studies conducted in the past two decades have shown that BRCA1 and BRCA2 play an essential role in protecting DNA from lesions that can lead to tumor formation. However, the factors that cause DNA lesions in BRCA1- and BRCA2-deficient … Continued
(October 13, 2017) The National Comprehensive Cancer Network currently recommends that early stage Ovarian Clear Cell Cancers be treated with adjuvant chemotherapy, or therapy given after the primary treatment as a way to lower the risk of recurrence. However, a retrospective study published recently in Annals of Oncology found that treating stage I endometrioid epithelial … Continued
(October 13, 2017) Every other year, the American Association for Cancer Research (AACR) brings together ovarian cancer researchers from around the world to share knowledge and encourage multi-disciplinary collaboration. At this year’s conference, held October 1-4 in Pittsburgh, Pennsylvania, a focus on critical questions led to energetic discussions about ways to take information from basic … Continued
(September 15, 2017) Two studies just confirmed that, depending on one’s genetic background, the standard treatment for epithelial ovarian cancer is most likely the best option. The studies, conducted with two different populations, showed that, although the outcomes conflicted one another, the option that offered the best progression free survival was the one already used. … Continued
(September 5, 2017) Researchers at the University of Pennsylvania recently uncovered a link between one’s resistance to common types of chemotherapy and one’s tumor BRCA1/2 mutation status. More specifically, they looked at both copies of the BRCA genes, one copy given by each parent. Until recently, it had been assumed that mutated BRCA gene left … Continued
Get email updates about research news, action alerts, and ways to join the fight.
